

Center for Cancer Genetic Epidemiology

Dr. Mark H. Skolnick/University of Utah/SLC, Utah

Established as a center in 1991 to utilize multiple approaches to study the genetic etiology of common cancers and their precursor lesions, currently breast cancer, melanoma, and prostate cancer and develop DNA diagnostics. Focus is on developing approaches to gene mapping and gene isolation and applying them in particular to the common cancers.

Overview	Technologies	Status	Economic Impact
<p>1994-95 State Contract \$20,000</p> <p>Matching Funds \$4,952,618</p> <p>Cumulative \$17,711,601</p> <p>Center Related Jobs 35</p> <p>Industry Jobs Created 50</p> <p>Benefiting Utah Companies:</p> <p>1994 Spin-off Companies 0</p> <p>Cum. Spin-off Companies 1</p> <p>Patents Applied 2</p> <p>Patents Issued 1</p> <p>License Agreements 1</p>	<ul style="list-style-type: none"> •Genetic Analysis •Gene Localization •Gene Discovery •Gene Diagnostics •Gene Therapies 	<ul style="list-style-type: none"> •Center has cloned the 17q linked breast cancer gene and the 9:-linked melanoma gene. •Pursuing gene isolation of a second breast cancer suspect gene. •Gathering more cancer families and preparing for linkage studies of breast, colon and prostate cancers. •Status of Center towards becoming self-sustaining is nearly complete. 	<ul style="list-style-type: none"> •Commercial partner, Myriad Genetics, Inc.'s economic impact on the State of Utah is the expenditure of approximately \$4,000,000 this year. They have 50 employees including 9 Ph.D's. •Myriad Genetics announced the identification of a tumor suppressing gene known as p16 that is suspected to be involved in a wide variety of cancers. Significant research will still be required to determine the causative involvement of the gene but the discovery is of potentially great importance in the understanding of cancerous tumor growth.